World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ChiCTR
Last refreshed on: 18 April 2017
Main ID:  ChiCTR-INR-16009989
Date of registration: 2017-02-01
Prospective Registration: No
Primary sponsor: Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
Public title: Berberine treat different curative effect observation of TCM syndrome type 2 diabetes
Scientific title: Berberine treat different curative effect observation of TCM syndrome type 2 diabetes
Date of first enrolment: 2016-12-01
Target sample size: Yin deficiency group hotness:48;Hot and humid trapped spleen group:48;Qi and Yin two virtual group:48;Qi deficiency and blood stasis group:48;
Recruitment status: Pending
URL:  http://www.chictr.org.cn/showproj.aspx?proj=16973
Study type:  Interventional study
Study design:  Randomized parallel controlled trial  
Phase:  New Treatment Measure Clinical Study
Countries of recruitment
China
Contacts
Name: Yang Hua   
Address:  725 South Wanping Road, Xuhui District, Shanghai
Telephone: +86 13916107306
Email: jenifer982969@hotmail.com
Affiliation:  Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
Name: Yang Hua   
Address:  725 South Wanping Road, Xuhui District, Shanghai
Telephone: +86 13916107306
Email: jenifer982969@hotmail.com
Affiliation:  Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
Key inclusion & exclusion criteria
Inclusion criteria: 1. Meet the western medicine diagnosis and syndrome differentiation of traditional Chinese medicine diagnosis and classification standards;
2. Aged between 18 to 75 years (including 18 years old, 75 years old), male and female;
3. After treatment with diet, exercise and oral glucose-lowering drugs poor glycemic control: 8 tendency/L < 15 tendency for L, fasting glucose or less tendency for 10 L < blood sugar 2 hours after meals < 20 tendency/L, and 8.0% or less hemoglobin a1c < 12 tendency for L. And use the original hypoglycemic regimen for more than 4 weeks;
4. Have informed consent and can cooperate with the visitor on schedule.

Exclusion criteria: 1. Pregnancy or breast-feeding women and may this medicine allergy;
2. Reluctant to partners (can't cooperate with diet control or does not affect curative effect in accordance with the provisions, medication);
3. Patients have been treated with berberine;
4. Mental illness, or with other serious primary diseases.
Nearly a month with diabetic ketoacidosis, hypertonic coma acute metabolic disorders.


Age minimum: 18
Age maximum: 75
Gender: Both
Health Condition(s) or Problem(s) studied
diabetes
Intervention(s)
Yin deficiency group hotness:On the basis of the original scheme combined with berberine, three times a day, each 0.3 ~ 0.3 g.;Hot and humid trapped spleen group:On the basis of the original scheme combined with berberine, three times a day, each 0.3 ~ 0.3 g.;Qi and Yin two virtual group:On the basis of the original scheme combined with berberine, three times a day, each 0.3 ~ 0.3 g.;Qi deficiency and blood stasis group:On the basis of the original scheme combined with berberine, three times a day, each 0.3 ~ 0.3 g.;
Primary Outcome(s)
Venous blood sugar on an empty stomach;Venous blood sugar 2 hours after breakfast;Glycated hemoglobin;
Secondary Outcome(s)
Secondary ID(s)
Source(s) of Monetary Support
Shanghai shen-kang hospital development center
Secondary Sponsor(s)
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history